McKesson's Option Care Investment Requires an Earnings Bridge

Start with McKesson’s actual investment

McKesson's proposed participation in the Option Care Health acquisition creates a specific modeling question: what earnings would the investment contribute to McKesson, and against which capital commitment should those earnings be assessed? The October 6 announcement says McKesson would invest approximately $1.4 billion for about 49%, while CD&R would hold approximately 51%.

The headline enterprise value describes the whole transaction; the minority equity investment describes one participant's contribution. Using the two interchangeably would distort a return calculation. A useful research note records the buyer's investment separately from the target's total transaction value, then identifies the earnings and cash distributions attributable to that investment.

This distinction matters before choosing any valuation multiple. An attractive operating business does not automatically imply an attractive return at every financing structure or purchase price. Start with the capital being committed, the economic claim received and the costs that sit between operating performance and the shareholder's return.

An equity-method contribution is a different model

McKesson intends to use equity-method accounting after closing, placing its share of Option Care's net income or loss in Other Income, net. The companies also describe a framework for a later acquisition of CD&R's interest, subject to conditions and regulatory approvals. That possible later step should remain separate from the initial minority investment.

For a preliminary model, build an explicit bridge from the investee's earnings to the investor's contribution. Do not insert the target's entire revenue line into the buyer's sales forecast simply because a transaction has been announced. Likewise, an ownership percentage multiplied by adjusted EBITDA is not automatically the amount that belongs in the buyer's net income.

Keep accounting contribution, actual distributions and investment funding costs on separate lines. The available transaction announcement does not by itself establish a complete recurring return estimate. Missing financing, purchase-accounting or distribution assumptions should remain labeled as missing, rather than being buried inside a single accretion percentage. A future move to full ownership would require its own analysis of price, timing and funding.

Use the operating baseline without reviving withdrawn guidance

Option Care's July 29 report provides a historical baseline: June-quarter revenue was $1.442 billion, GAAP net income was $53.9 million and adjusted EBITDA was $117.5 million. Quarterly operating cash flow was $184 million. These are different measures for the same business, not interchangeable estimates of distributable earnings.

The October transaction announcement withdrew Option Care's previous guidance. Its next results release is expected November 4, without a live earnings call. A historical forecast should therefore not appear in a model as current management guidance merely because the numbers remain available in an older document.

A practical update sheet should label every input as reported history, a current company expectation or an analyst assumption. Retain the June-quarter figures to examine operating progress when the next report arrives, but avoid multiplying one quarter by four and presenting the result as a forecast. A transaction can alter financing and accounting as well as ownership.

The company defines adjusted EBITDA by excluding items that include interest, taxes, depreciation, amortization and stock-based compensation. For this investment question, those exclusions explain why operating momentum requires a further bridge before it can support a claim about earnings attributable to McKesson.

Track completion before counting the contribution

Option Care's SEC filing says the merger agreement was signed October 5 and eligible common shares would convert into $32.05 cash per share, without interest, at the merger's effective time. The filing also describes ordinary-course operating covenants during the pending transaction. The announcement anticipates completion in the first half of 2027, subject to shareholder and regulatory approvals.

For McKesson research, keep a pending-deal schedule alongside the operating model. A signed agreement establishes a proposed transaction; it does not establish that the investment is already earning a full year's contribution. Changes in the expected completion date should flow through the period included in a forecast.

Evidence that would improve the assessment includes clearer funding terms, subsequent operating results, closing disclosures and the first reported investment contribution. Evidence that would weaken it includes delays, deteriorating target economics or funding requirements that reduce the expected return. Until those inputs become clearer, the useful conclusion is a defined research task: connect the minority capital commitment to attributable earnings and cash, with the timing and assumptions visible.